![Ellen Holm Nielsen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ellen Holm Nielsen
Corporate Officer/Principal en University of Southern Denmark .
Cargos activos de Ellen Holm Nielsen
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
University of Southern Denmark | Corporate Officer/Principal | - | - |
University of California, Berkeley | Corporate Officer/Principal | - | - |
Albert Einstein College of Medicine, Inc. | Corporate Officer/Principal | 14/08/2009 | - |
University of Copenhagen | Corporate Officer/Principal | - | - |
Historial de carrera de Ellen Holm Nielsen
Antiguos cargos conocidos de Ellen Holm Nielsen.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Profylakse ApS
![]() Profylakse ApS Pharmaceuticals: MajorHealth Technology Profylakse is a Danish biotech company, founded in 1999 by scientists from University of Southern Denmark. Profylakse has an experienced development team, working within microbiology, immunology and protein chemistry for 3 decades. Its focus is on the development of antiviral, not vaccines, especially against influenza and parainfluenza viruses. This has resulted in its antiviral recombinant SAP. Profylakse´s investor base is the Danish Technological Institute and the South Danish Innovations. | Director/Miembro de la Junta | - | 22/11/2013 |
Estadísticas
Internacional
Dinamarca | 4 |
Estados Unidos | 3 |
Operativa
Corporate Officer/Principal | 4 |
Director/Board Member | 1 |
Sectorial
Consumer Services | 5 |
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Profylakse ApS
![]() Profylakse ApS Pharmaceuticals: MajorHealth Technology Profylakse is a Danish biotech company, founded in 1999 by scientists from University of Southern Denmark. Profylakse has an experienced development team, working within microbiology, immunology and protein chemistry for 3 decades. Its focus is on the development of antiviral, not vaccines, especially against influenza and parainfluenza viruses. This has resulted in its antiviral recombinant SAP. Profylakse´s investor base is the Danish Technological Institute and the South Danish Innovations. | Health Technology |
- Bolsa de valores
- Insiders
- Ellen Holm Nielsen
- Experiencia